CAMRF (Camurus AB) Short Percentage of Float


CAMRF Camurus AB CAMRF
79 GF Score
Price $54.00
GF Value $83.22
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CAMRF vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Camurus AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camurus AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Camurus AB's Short Percentage of Float falls into.


CAMRF
79GF Score
Camurus AB CAMRF
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 35.1% below its estimated GF Value™ of $83.22. GuruFocus considers Camurus AB to be Significantly Undervalued.

Key valuation signals for CAMRF:

  • Short Percentage of Float:
  • GF Value™: $83.22 vs. price of $54.00 (35.1% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score

Get the complete analysis for CAMRF

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$83.22
GF Value